Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 04, 2025 07:30 ET | Source: Reunion Neuroscience Inc.

Reunion Neuroscience Announces Participation in Premiere Maternal Mental Health Event

Reunion to Participate in the ‘New Treatment Options Panel’ Discussion at the 2025 Maternal Mental Health FORUM on March 18 at 2:30 p.m. ET Patient Enrollment Ongoing in Reunion’s Phase 2, 35 Site...
January 06, 2025 07:30 ET | Source: Reunion Neuroscience Inc.

Reunion Neuroscience Announces Program Updates and Highlights Anticipated 2025 Milestones

Patient Enrollment Ongoing in Phase 2 RECONNECT Trial of RE104 in Postpartum Depression (PPD); Topline Data Anticipated Mid-2025 Initiation of Phase 2 REKINDLE Trial of RE104 in Adjustment Disorder...
December 11, 2024 07:30 ET | Source: Reunion Neuroscience Inc.

Reunion Neuroscience Presented RE104 Phase 1 Data at the 2024 American College of Neuropsychopharmacology (ACNP) 63rd Annual Meeting

MORRISTOWN, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health...
October 09, 2024 07:30 ET | Source: Reunion Neuroscience Inc.

Reunion Neuroscience Partners with Seleni Institute on Effective Diagnosis and Treatment of Maternal Mental Health Disorders

Reunion to Sponsor Scholarships that will Train Healthcare Professionals on Maternal Mental Health Disorders, including Postpartum Depression Reunion’s Phase 2 RECONNECT Study in Postpartum...
September 10, 2024 07:30 ET | Source: Reunion Neuroscience Inc.

Reunion Neuroscience Appoints Mark Pollack, M.D., as Chief Medical Officer

MORRISTOWN, N.J., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health...
September 04, 2024 07:30 ET | Source: Reunion Neuroscience Inc.

Reunion Neuroscience Joins the Is Mom OK? Initiative Recognizing Maternal Suicide Prevention Month

MORRISTOWN, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health...
July 23, 2024 07:30 ET | Source: Reunion Neuroscience Inc.

Reunion Neuroscience Inc. Announces First Patient Dosed in Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression

MORRISTOWN, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to pushing the boundaries of neuroscience, today announced that...
May 20, 2024 07:30 ET | Source: Reunion Neuroscience Inc.

Reunion Neuroscience Announces Publication of Results from Early Preclinical Studies Demonstrating the Potential of RE104 for Development in Depressive Disorders

Reunion’s lead asset, RE104, is a potential best-in-class, clinical-stage serotonergic psychedelic drug candidate designed as a safe, fast-acting, short duration therapy to provide lasting benefits to...
May 02, 2024 06:30 ET | Source: Reunion Neuroscience Inc.

Reunion Neuroscience Inc. Announces $103 Million Series A Financing Co-Led by MPM BioImpact and Novo Holdings

Company is advancing RE104, its proprietary, clinical-stage serotonergic psychedelic drug candidate designed as a safe, fast-acting, short duration therapy to provide lasting benefits to patients with...
April 03, 2024 07:30 ET | Source: Reunion Neuroscience Inc.

Reunion Neuroscience Inc. Announces Upcoming Presentations at the Anxiety and Depression Association of America (ADAA) 2024 Conference

MORRISTOWN, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc., a venture backed clinical-stage biopharmaceutical company committed to pushing the boundaries of neuroscience, today...